AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 34636433 — intervention group
Group type: EXPERIMENTAL
Intervention: High-volume centers
Number of subjects: 0
Study 34636433 — intervention group
Group type: COMPARATOR
Intervention: Low-volume centers
Number of subjects: 0
Study 34939887 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical Component Summary (PCS) score at 12 months
Number of subjects: 400
Study 34939887 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in PCS score between 6 and 12 months
Number of subjects: 400
Study 34939887 — intervention group
Group type: EXPERIMENTAL
Intervention: Cohen's method for estimating MCID from PCS score distribution
Number of subjects: 400
Study 35058605 — intervention group
Group type: EXPERIMENTAL
Intervention: Low free sugar diet
Number of subjects: 43
Study 35058605 — intervention group
Group type: COMPARATOR
Intervention: Usual diet
Number of subjects: 43
Study 33913678 — intervention group
Group type: EXPERIMENTAL
Intervention: PRD-guided remifentanil administration
Number of subjects: 100
Study 33913678 — intervention group
Group type: COMPARATOR
Intervention: Standard anaesthesia care (control)
Number of subjects: 100
Study 36355371 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose interleukin 2 (LD-IL-2)
Number of subjects: 60
Study 36355371 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 32513260 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidant dressing therapy
Number of subjects: 0
Study 32513260 — intervention group
Group type: COMPARATOR
Intervention: Standard wound dressing
Number of subjects: 0
Study 33303279 — intervention group
Group type: EXPERIMENTAL
Intervention: Automatic lancet
Number of subjects: 60
Study 33303279 — intervention group
Group type: COMPARATOR
Intervention: Manual lancet
Number of subjects: 60
Study 32850394 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly TPF (Docetaxel, Cisplatin, Fluorouracil)
Number of subjects: 82
Study 32850394 — intervention group
Group type: COMPARATOR
Intervention: 3-weekly TPF (Docetaxel, Cisplatin, Fluorouracil)
Number of subjects: 82
Study 32850394 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly TPF
Number of subjects: 82
Study 32850394 — intervention group
Group type: COMPARATOR
Intervention: 3-weekly TPF
Number of subjects: 82
Study 35379618 — intervention group
Group type: EXPERIMENTAL
Intervention: DRE with daytime compression garment during exercise
Number of subjects: 60
Study 35379618 — intervention group
Group type: EXPERIMENTAL
Intervention: DRE with adjustable compression wrap during exercise
Number of subjects: 60
Study 35379618 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 60
Study 34098931 — intervention group
Group type: EXPERIMENTAL
Intervention: Flipped Classroom (FC)
Number of subjects: 40
Study 34098931 — intervention group
Group type: COMPARATOR
Intervention: Live Demonstration (LD)
Number of subjects: 40
Study 34098931 — intervention group
Group type: EXPERIMENTAL
Intervention: Both LD and FC
Number of subjects: 40
Study 32955273 — intervention group
Group type: EXPERIMENTAL
Intervention: REDI preschool intervention
Number of subjects: 294
Study 32955273 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 294
Study 34627665 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoral vertical ramus osteotomy (IVRO)
Number of subjects: 98
Study 34627665 — intervention group
Group type: COMPARATOR
Intervention: Sagittal split ramus osteotomy (SSRO)
Number of subjects: 98
Study 32663139 — intervention group
Group type: EXPERIMENTAL
Intervention: LowSalt4Life intervention (App group)
Number of subjects: 50
Study 32663139 — intervention group
Group type: COMPARATOR
Intervention: No App group (usual dietary advice)
Number of subjects: 50
Study 34346833 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccination at baseline (intervention)
Number of subjects: 11391
Study 34346833 — intervention group
Group type: COMPARATOR
Intervention: Control group (vaccination at 12 months)
Number of subjects: 11391
Study 33185028 — intervention group
Group type: EXPERIMENTAL
Intervention: Brigatinib 180 mg once daily (q.d.) with a 7-day lead-in at 90 mg
Number of subjects: 0
Study 33185028 — intervention group
Group type: COMPARATOR
Intervention: Brigatinib 90 mg once daily (q.d.)
Number of subjects: 0
Study 33185028 — intervention group
Group type: EXPERIMENTAL
Intervention: Brigatinib (general exposure)
Number of subjects: 0
Study 32962509 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow speed condition
Number of subjects: 21
Study 32962509 — intervention group
Group type: EXPERIMENTAL
Intervention: All speed conditions
Number of subjects: 21
Study 33214444 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgeons influenced by the belief that pursuing surgery gives the patient or family time to cope with the patient's condition
Number of subjects: 2161
Study 33214444 — intervention group
Group type: COMPARATOR
Intervention: Surgeons whose decisions were influenced by time required to discuss non-operative treatments
Number of subjects: 2161
Study 33214444 — intervention group
Group type: COMPARATOR
Intervention: Surgeons whose decisions were influenced by the consulting intensivists' endorsement of operative intervention
Number of subjects: 2161
Study 36432562 — intervention group
Group type: EXPERIMENTAL
Intervention: H2-producing milk
Number of subjects: 0
Study 36432562 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 33417414 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid Intraplaque Hemorrhage (IPH) in patients with RAO
Number of subjects: 14
Study 33417414 — intervention group
Group type: COMPARATOR
Intervention: Control group (patients without prior ischemic event)
Number of subjects: 14
Study 33417414 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid IPH
Number of subjects: 14
Study 32449335 — intervention group
Group type: COMPARATOR
Intervention: Conventional general anesthesia
Number of subjects: 80
Study 32449335 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional general anesthesia with extra administration of intraoperative magnesium sulphate
Number of subjects: 80
Study 35704292 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous Vitamin C (50 mg/kg every 6 hours for up to 96 hours)
Number of subjects: 872
Study 35704292 — intervention group
Group type: COMPARATOR
Intervention: Placebo (matched control)
Number of subjects: 872
Study 35704292 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous Vitamin C
Number of subjects: 872
Study 35704292 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 872
Study 34864925 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine (DHA-PQ) 120/960 mg
Number of subjects: 748
Study 34864925 — intervention group
Group type: COMPARATOR
Intervention: Sulfadoxine-pyrimethamine (SP) 1500/75 mg
Number of subjects: 748
Study 34864925 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine (DHA-PQ)
Number of subjects: 748
Study 32986498 — intervention group
Group type: EXPERIMENTAL
Intervention: Venetoclax plus Rituximab (VenR) for 2 years
Number of subjects: 389
Study 32986498 — intervention group
Group type: COMPARATOR
Intervention: Bendamustine plus Rituximab (BR) for 6 cycles
Number of subjects: 389
Study 32986498 — intervention group
Group type: EXPERIMENTAL
Intervention: VenR with undetectable minimal residual disease (uMRD) at end of combination therapy (EOCT)
Number of subjects: 389
Study 32986498 — intervention group
Group type: EXPERIMENTAL
Intervention: VenR followed by ibrutinib as first therapy after progression
Number of subjects: 389
Study 32986498 — intervention group
Group type: EXPERIMENTAL
Intervention: VenR followed by venetoclax-based regimen
Number of subjects: 389
Study 32986498 — intervention group
Group type: EXPERIMENTAL
Intervention: VenR
Number of subjects: 389
Study 34994838 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% Patent Blue Dye injection in the upper outer quadrant of the breast (validated by radioactive nanocolloid)
Number of subjects: 279
Study 34994838 — intervention group
Group type: COMPARATOR
Intervention: Classic retro-areolar patent blue injection
Number of subjects: 279
Study 33926211 — intervention group
Group type: EXPERIMENTAL
Intervention: Advice leaflet
Number of subjects: 116
Study 33926211 — intervention group
Group type: EXPERIMENTAL
Intervention: Advice video
Number of subjects: 116
Study 33926211 — intervention group
Group type: COMPARATOR
Intervention: Face-to-face therapy
Number of subjects: 116
Study 32265291 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory load intensity 20% of maximum inspiratory pressure
Number of subjects: 29
Study 32265291 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory load intensity 40% of maximum inspiratory pressure
Number of subjects: 29
Study 32265291 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal interface
Number of subjects: 29
Study 32265291 — intervention group
Group type: COMPARATOR
Intervention: Oral interface
Number of subjects: 29
Study 34479838 — intervention group
Group type: EXPERIMENTAL
Intervention: apalutamide (240 mg/d)
Number of subjects: 1207
Study 34479838 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 1207
Study 32662379 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal weight at enrollment (12-20 weeks)
Number of subjects: 46
Study 32662379 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal weight at 36 weeks
Number of subjects: 46
Study 33055173 — intervention group
Group type: EXPERIMENTAL
Intervention: Vorinostat plus Sirolimus (V+S)
Number of subjects: 40
Study 33055173 — intervention group
Group type: EXPERIMENTAL
Intervention: Vorinostat plus Everolimus (V+E)
Number of subjects: 40
Study 35212402 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine-prilocaine cream (5 ml of 5%)
Number of subjects: 210
Study 35212402 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal misoprostol (200 μg)
Number of subjects: 210
Study 35212402 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 210
Study 35212402 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine-prilocaine cream and misoprostol
Number of subjects: 210
Study 33894061 — intervention group
Group type: EXPERIMENTAL
Intervention: OPEN‐DRUG+INST
Number of subjects: 0
Study 33894061 — intervention group
Group type: EXPERIMENTAL
Intervention: OPEN‐DRUG+INST+COND
Number of subjects: 0
Study 33894061 — intervention group
Group type: EXPERIMENTAL
Intervention: PLAC+INST+COND
Number of subjects: 0
Study 33894061 — intervention group
Group type: COMPARATOR
Intervention: HIDDEN‐DRUG
Number of subjects: 0
Study 32194214 — intervention group
Group type: EXPERIMENTAL
Intervention: Asthma Outcome Expectation‐self‐efficacy subscale (AOE‐SE)
Number of subjects: 371
Study 32194214 — intervention group
Group type: EXPERIMENTAL
Intervention: Asthma Management Index‐self‐efficacy subscale (AMI‐SE)
Number of subjects: 371
Study 32194214 — intervention group
Group type: EXPERIMENTAL
Intervention: Asthma Self‐Efficacy scale (ASE)
Number of subjects: 371
Study 35353961 — intervention group
Group type: EXPERIMENTAL
Intervention: Mini-slings
Number of subjects: 596
Study 35353961 — intervention group
Group type: COMPARATOR
Intervention: Midurethral slings
Number of subjects: 596
Study 34684557 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium Phosphate (SP) supplementation (50 mg·kg‐1 of fat‐free mass/day)
Number of subjects: 20
Study 34684557 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 32367882 — intervention group
Group type: EXPERIMENTAL
Intervention: Surface coated with G‐Coat Plus (GC)
Number of subjects: 70
Study 32367882 — intervention group
Group type: COMPARATOR
Intervention: Uncoated
Number of subjects: 70
Study 36275396 — intervention group
Group type: EXPERIMENTAL
Intervention: Group BR (20 ml of 0.33% ropivacaine plus 1 mg butorphanol)
Number of subjects: 74
Study 36275396 — intervention group
Group type: EXPERIMENTAL
Intervention: Group BR
Number of subjects: 74
Study 36275396 — intervention group
Group type: COMPARATOR
Intervention: Group R (20 ml of 0.33% ropivacaine plus 1 ml normal saline)
Number of subjects: 74
Study 34125374 — intervention group
Group type: COMPARATOR
Intervention: Adjuvant chemotherapy alone
Number of subjects: 159
Study 34125374 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiation and chemotherapy at diagnosis
Number of subjects: 159
Study 34597436 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg/kg ketamine
Number of subjects: 35
Study 34597436 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 mg/kg ketamine
Number of subjects: 35
Study 34597436 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (placebo)
Number of subjects: 35
Study 32985910 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher levels of HDL-C
Number of subjects: 275
Study 32985910 — intervention group
Group type: COMPARATOR
Intervention: Total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), triglycerides (TG)
Number of subjects: 275
Study 35726856 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 g·kg‐1 dextrose, identified as creatine (Cr-True)
Number of subjects: 15
Study 35726856 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 g·kg‐1 dextrose, identified as creatine (Cr-False)
Number of subjects: 15
Study 35726856 — intervention group
Group type: COMPARATOR
Intervention: 0.3 g·kg‐1 dextrose placebo (PLC)
Number of subjects: 15
Study 35726856 — intervention group
Group type: COMPARATOR
Intervention: nothing (CON)
Number of subjects: 15
Study 32243248 — intervention group
Group type: EXPERIMENTAL
Intervention: Activated charcoal‐based powder
Number of subjects: 45
Study 32243248 — intervention group
Group type: COMPARATOR
Intervention: 1450‐ppm F toothpaste (control group)
Number of subjects: 45
Study 32243248 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% carbamide peroxide
Number of subjects: 45
Study 35331337 — intervention group
Group type: EXPERIMENTAL
Intervention: For Our Children's Sake (FOCS) intervention
Number of subjects: 35
Study 33661967 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% topical diclofenac
Number of subjects: 67
Study 33661967 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67
Study 32092439 — intervention group
Group type: EXPERIMENTAL
Intervention: Individually-targeted weekly coupons (valued up to $10) with brief nutrition education for 13 weeks
Number of subjects: 224
Study 32092439 — intervention group
Group type: COMPARATOR
Intervention: Weekly untargeted nutrition education and occasional generic coupons
Number of subjects: 224
Study 32762784 — intervention group
Group type: EXPERIMENTAL
Intervention: Flipped Classroom (FC)
Number of subjects: 103
Study 32762784 — intervention group
Group type: COMPARATOR
Intervention: Traditional Lecture‐based Classroom (TLC)
Number of subjects: 103
Study 32026820 — intervention group
Group type: EXPERIMENTAL
Intervention: Telerehabilitation (n=35; technology-based home exercise program using an iPad application)
Number of subjects: 69
Study 32026820 — intervention group
Group type: EXPERIMENTAL
Intervention: Telerehabilitation (n=35)
Number of subjects: 69
Study 32026820 — intervention group
Group type: COMPARATOR
Intervention: In-person outpatient physiotherapy (control group n=35)
Number of subjects: 69
Study 36227309 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified clinical reminder intervention (N = 44 teams)
Number of subjects: 28441
Study 36227309 — intervention group
Group type: COMPARATOR
Intervention: Status quo (N = 40 teams)
Number of subjects: 28441
Study 34183350 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital cognitive-behavioural therapy for insomnia (dCBT-I)
Number of subjects: 800
Study 34183350 — intervention group
Group type: COMPARATOR
Intervention: Patient education about insomnia (PE)
Number of subjects: 800
Study 35218300 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate antiretroviral therapy (ART) offered through trial clinics in intervention clusters
Number of subjects: 0
Study 35218300 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving ART according to national guidelines
Number of subjects: 0
Study 32012085 — intervention group
Group type: EXPERIMENTAL
Intervention: mHealth interventions
Number of subjects: 0
Study 32012085 — intervention group
Group type: EXPERIMENTAL
Intervention: mHealth evaluation
Number of subjects: 0
Study 33307388 — intervention group
Group type: EXPERIMENTAL
Intervention: RFD-RFL index scores
Number of subjects: 167
Study 33307388 — intervention group
Group type: EXPERIMENTAL
Intervention: Endorsing more RFD relative to RFL
Number of subjects: 167
Study 32223612 — intervention group
Group type: EXPERIMENTAL
Intervention: Music plus relaxation suggestions
Number of subjects: 66
Study 32223612 — intervention group
Group type: COMPARATOR
Intervention: Music alone
Number of subjects: 66
Study 32223612 — intervention group
Group type: COMPARATOR
Intervention: Silence
Number of subjects: 66
Study 35324053 — intervention group
Group type: COMPARATOR
Intervention: Connective Tissue Graft (CTG)
Number of subjects: 45
Study 35324053 — intervention group
Group type: EXPERIMENTAL
Intervention: Porcine-Derived Collagen Matrix (PDCM)
Number of subjects: 45
Study 33347771 — intervention group
Group type: EXPERIMENTAL
Intervention: Pollen count rises past medium or higher thresholds
Number of subjects: 0
Study 33347771 — intervention group
Group type: EXPERIMENTAL
Intervention: Pollen count rises past established thresholds
Number of subjects: 0
Study 33420853 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed non-thermal atmospheric pressure nitrogen plasma
Number of subjects: 25
Study 33420853 — intervention group
Group type: COMPARATOR
Intervention: Long-pulsed Nd:YAG laser
Number of subjects: 25
Study 33420853 — intervention group
Group type: EXPERIMENTAL
Intervention: Both methods
Number of subjects: 25
Study 35613846 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal transcranial direct current stimulation (a‐tDCS)
Number of subjects: 20
Study 35613846 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 20
Study 33931570 — intervention group
Group type: EXPERIMENTAL
Intervention: FESCE-based protocolised rehabilitation
Number of subjects: 150
Study 33931570 — intervention group
Group type: COMPARATOR
Intervention: Standard rehabilitation
Number of subjects: 150
Study 36335970 — intervention group
Group type: EXPERIMENTAL
Intervention: Active eradication (oral clarithromycin 500 mg, metronidazole 400 mg, and lansoprazole 30 mg, twice daily for 1 week)
Number of subjects: 5352
Study 36335970 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 5352
Study 36335970 — intervention group
Group type: EXPERIMENTAL
Intervention: Active eradication
Number of subjects: 5352
Study 32290271 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey protein isolate (WPI) 50g/daily for 12 weeks
Number of subjects: 99
Study 32290271 — intervention group
Group type: COMPARATOR
Intervention: Iso-caloric carbohydrate (CHO) control for 12 weeks
Number of subjects: 99
Study 36471449 — intervention group
Group type: EXPERIMENTAL
Intervention: Bazedoxifene plus conjugated estrogen
Number of subjects: 0
Study 34697593 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemigliptin 50 mg daily along with standard care for diabetes mellitus for 6 months
Number of subjects: 201
Study 34697593 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 201
Study 36073578 — intervention group
Group type: EXPERIMENTAL
Intervention: Suture fixation of the parietal peritoneum
Number of subjects: 14
Study 36073578 — intervention group
Group type: COMPARATOR
Intervention: Tack fixation of the parietal peritoneum
Number of subjects: 14
Study 34332741 — intervention group
Group type: EXPERIMENTAL
Intervention: Next Day Discharge (NDD) group (≤1 day hospital stay)
Number of subjects: 22035
Study 34332741 — intervention group
Group type: COMPARATOR
Intervention: Non-Next Day Discharge (non-NDD) group (>1 day hospital stay)
Number of subjects: 22035
Study 34098030 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly cisplatin (7 doses of 40 mg/m2)
Number of subjects: 189
Study 34098030 — intervention group
Group type: COMPARATOR
Intervention: Cetuximab (loading dose of 400 mg/m2 followed by 7 weekly doses of 250 mg/m2)
Number of subjects: 189
Study 34098030 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 189
Study 33993779 — intervention group
Group type: EXPERIMENTAL
Intervention: Sexual Assault condition (SA)
Number of subjects: 782
Study 33993779 — intervention group
Group type: COMPARATOR
Intervention: Health condition
Number of subjects: 782
Study 33993779 — intervention group
Group type: COMPARATOR
Intervention: Crime condition
Number of subjects: 782
Study 33993779 — intervention group
Group type: COMPARATOR
Intervention: Alcohol condition
Number of subjects: 782
Study 33811818 — intervention group
Group type: COMPARATOR
Intervention: AGRI-NUT group
Number of subjects: 148
Study 33811818 — intervention group
Group type: COMPARATOR
Intervention: AGRI-NUT+PLA group
Number of subjects: 148
Study 33811818 — intervention group
Group type: COMPARATOR
Intervention: AGRI group
Number of subjects: 148
Study 32650801 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP) injection (8 mL)
Number of subjects: 40
Study 32650801 — intervention group
Group type: COMPARATOR
Intervention: Corticosteroid (CS) injection (1 mL of 40 mg/mL triamcinolone acetonide plus 5 mL of 2% lidocaine)
Number of subjects: 40
Study 34971028 — intervention group
Group type: EXPERIMENTAL
Intervention: iSupport-Portugal
Number of subjects: 42
Study 34971028 — intervention group
Group type: COMPARATOR
Intervention: Control (e-book)
Number of subjects: 42
Study 33627163 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal manipulation (four times over two weeks)
Number of subjects: 132
Study 33627163 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal manipulation
Number of subjects: 132
Study 36261132 — intervention group
Group type: EXPERIMENTAL
Intervention: LISA
Number of subjects: 42
Study 36261132 — intervention group
Group type: COMPARATOR
Intervention: INSURE
Number of subjects: 42
Study 33484151 — intervention group
Group type: EXPERIMENTAL
Intervention: SHHC intervention (n = 101)
Number of subjects: 194
Study 33484151 — intervention group
Group type: COMPARATOR
Intervention: Education-only control intervention (n = 93)
Number of subjects: 194
Study 35657603 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-based Diagnostic Engine (CDE)
Number of subjects: 212
Study 33479505 — intervention group
Group type: EXPERIMENTAL
Intervention: Informative and motivational video messages
Number of subjects: 0
Study 33479505 — intervention group
Group type: EXPERIMENTAL
Intervention: Small monetary incentives
Number of subjects: 0
Study 33099944 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy (group A)
Number of subjects: 146
Study 33099944 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent chemoradiotherapy (group B)
Number of subjects: 146